- GSK culls cough program for drug at the heart of $2B Bellus bet after Phase 3 failCamlipixant, which GSK picked up in its $2 billion buyout of Bellus Health in April 2023, “is unlikely to transform patient care,” the pharma said.BioSpace · 10d ago↗ source
- BlossomHill eyes IPO as fertilizer to grow taller in crowded cancer fieldsAnother biotech is squeezing into the crowded IPO waiting room just in time for the weekend. BlossomHill Therapeutics, a San Diego-based oncology outfit focused on small molecules, has filed paperw…Fierce Biotech · 10d ago↗ source
- Who can access testosterone hormone medication in the U.S.?Wildfire smoke health hazards, a new idea for treating Duchenne, and more health news from Morning RoundsSTAT